TY -的T1与epopro应用波生坦的组合stenol in pulmonary arterial hypertension: BREATHE-2 JF - European Respiratory Journal JO - Eur Respir J SP - 353 LP - 359 DO - 10.1183/09031936.04.00028404 VL - 24 IS - 3 AU - Humbert, M. AU - Barst, R.J. AU - Robbins, I.M. AU - Channick, R.N. AU - Galiè, N. AU - Boonstra, A. AU - Rubin, L.J. AU - Horn, E.M. AU - Manes, A. AU - Simonneau, G. Y1 - 2004/09/01 UR - //www.qdcxjkg.com/content/24/3/353.abstract N2 - The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial hypertension (PAH) was investigated. In this double-blind, placebo-controlled prospective study, 33 patients with PAH started epoprostenol treatment (2 ng·kg−1min−1 starting dose, up to 14±2 ng·kg−1min−1 at week 16) and were randomised for 16 weeks in a 2:1 ratio to bosentan (62.5 mg b.i.d for 4 weeks then 125 mg b.i.d) or placebo. Haemodynamics, exercise capacity and functional class improved in both groups at week 16. In the combination treatment group, there was a trend for a greater (although nonsignificant) improvement in all measured haemodynamic parameters. There were four withdrawals in the bosentan/epoprostenol group (two deaths due to cardiopulmonary failure, one clinical worsening, and one adverse event) and one withdrawal in the placebo/epoprostenol group (adverse event). This study showed a trend but no statistical significance towards haemodynamics or clinical improvement due to the combination of bosentan and epoprostenol therapy in patients with pulmonary arterial hypertension. Several cases of early and late major complications were reported. Additional information is needed to evaluate the risk/benefit ratio of combined bosentan-epoprostenol therapy in pulmonary arterial hypertension. This study was supported by Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. ER -